Spectrum Pharmaceuticals, Inc. SPPI announced that it has added two new cohorts in the phase II study — ZENITH20. The study is evaluating its pipeline candidate, poziotinib, in non-small cell lung ...
Spectrum Pharmaceuticals, Inc. SPPI announced positive data from a phase III study, ADVANCE, evaluating its lead pipeline candidate, Rolontis, for management of chemotherapy-induced neutropenia in ...
The Middle Class Tax Relief and Job Creation Act of 2012 (the same law that allowed incentive auction of TV spectrum) required the General Accounting Office to conduct a study of spectrum efficiency, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback